In a breakthrough discovery that changes how we understand T cells and with implications of how we can better engineer custom immune responses to fight disease, Institute for Systems Biology researchers showed that the different disease-fighting functions of different T cells are determined by the genetically encoded T-cell receptor sequence that are unique to those cells.
By using a computer model to understand the adaptions of Mycobacterium tuberculosis (Mtb), the pathogen that causes tuberculosis, researchers at ISB have identified a network within Mtb that allows it to tolerate and resist drug therapies. This work is published in Cell Reports.
Supplementing the standard of treatment for Alzheimer’s disease patients with personalized lifestyle coaching leads to less cognitive decline compared to standard of treatment alone, according to an ISB-led two-year study. The results were published in the Journal of Alzheimer’s Disease.
Pregnant people who are vaccinated are less likely to contract COVID-19 than unvaccinated pregnant people, and those vaccinated and boosted are less likely to get COVID than those who are vaccinated only, according to the first-ever large study of boosters and pregnancy.
Dr. Jennifer Hadlock – an expert in machine learning, immune-mediated inflammatory disease, and maternal/fetal health – has been promoted to associate professor. The Hadlock Lab is an interdisciplinary team that aims to accelerate translational research by integrating clinical data into systems biology at scale.
ISB researchers have constructed biological body mass index (BMI) measures that offer a more accurate representation of metabolic health and are more varied, informative and actionable than the traditional, long-used BMI equation. The work was published in the journal Nature Medicine.
Scientists for the first time have used CRISPR to substitute a gene to treat patients with cancer. The remarkable findings were published in the journal Nature and presented at the Society for Immunotherapy of Cancer (SITC) 2022.
ISB researchers have shown which blood metabolites are associated with the gut microbiome, genetics, or the interplay between both. Their findings, published in the journal Nature Metabolism, have promising implications for guiding targeted therapies designed to alter the composition of the blood metabolome to improve human health.
The NCI awarded ISB a 5-year, $13 million grant to lead a comprehensive cancer center and study sequential combinations of targeted inhibitors and immunotherapies. The program is designed to determine if the treatments yield greater patient benefit when administered in sequence rather than as monotherapies or as simultaneously administered combinations.
New ISB research shows that different patient responses to statins can be explained by the variation in the human microbiome. The findings were published in the journal Med, and suggest that microbiome monitoring could be used to help optimize personalized statin treatments.
A just-published study provides new information about which hospitalized COVID-19 patients are most likely to need mechanical ventilation or to die. The ISB-led work shows that vital signs and lab results at the time of hospital admission are the most accurate predictors of disease severity, more so than comorbidities and demographics.
As part of a massive nationwide effort, ISB is leading a multi-site consortium for the NIH RECOVER (Researching COVID to Enhance Recovery) Initiative. The Pacific Northwest consortium is made up of ISB, Providence, Swedish, and University of Washington School of Medicine.
Dr. Jim Heath was announced as a newly elected Fellow of the American Academy for Cancer Research (AACR) Academy Class of 2022. “I am honored and humbled to be recognized as part of this renowned group of researchers who have done so much to move our understanding of cancer forward,” Heath said.
Researchers have identified several factors that can be measured at the initial point of COVID-19 diagnosis that anticipate if a patient is likely to develop long COVID. They also found that mild cases of COVID-19, not just severe cases, are associated with long COVID. Their findings were published by the journal Cell.
An ISB-led study examined the electronic health records of more than 18,000 people with SARS-CoV-2 tests during pregnancy, and found that those who contracted COVID-19 while pregnant were more likely to have poor birth outcomes including preterm birth, small for gestational age, low birth weight, and stillbirth.
Dr. Anna Kuchina has joined ISB as assistant professor, and is our newest faculty member. Kuchina comes to ISB after completing her postdoctoral training in the Seelig Lab at the University of Washington. In this Q&A, we delve into Kuchina’s research career to date, her research areas of interest, and much more.
Tuberculosis (TB) is the world’s second leading infectious disease killer after COVID-19. Drug resistance to TB is a public health crisis. ISB researchers have developed algorithms to predict the efficacy of drugs in treating Mycobacterium tuberculosis (MTB), the causative agent for TB. These research findings were published in the journal Cell Reports Methods.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.